On April 15, 2021 Iktos’s AI technology, reported that based on deep generative models, helps bring speed and efficiency to the drug discovery process (Press release, Iktos, APR 15, 2021, View Source [SID1234580475]). Iktos’ technology automatically designs virtual novel molecules that have all of the characteristics of a successful drug molecule.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Iktos AI is the first company to release user-friendly and high-performance de novo design software for multi-parameter optimization that can be used by any medicinal or computational chemist, whatever their level of expertise, in deep learning and computer programming.

BioExcel is partnering with Iktos on the application of advanced molecular modelling and simulation techniques to expedite drug design.